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The monoclonal antibody (mAb) market has been presenting a significant growth rate in the last two decades, 
which increased the interest of biopharmaceutical companies in this product class. Many improvements have 
been achieved in the upstream processing of mAbs, leading to significant increases in bioreactor titers. 
However, the production costs are still high, especially due to downstream processing costs, which can 
represent a major part of the of overall production costs. Traditional mAb platform processes include a very 
selective, but high-cost Protein A (PrA) affinity chromatography as the first purification step (capture). Several 
approaches have been recently explored in order to replace PrA chromatography. In this work, we propose a 
new, low-cost strategy for integrating clarification and capture step for mAbs using flocculation followed by a 
straight-through process with single-pass tangential flow filtration (TFF) and suspension anion-exchange (AEX) 
chromatography. First, the recombinant anti-IL8 mAb were produced by CHO-DP12 cells (ATCC, USA) in shake 
flasks at 180 rpm and 37°C using TC-LECC medium (Xell, Germany). After harvest, cells were flocculated using 
5 pg per total cells at pH 6.5, allowing 15 min for settling of cells. Subsequently, the resulting supernatant and a 
Q-Sepharose resin (GE, Sweden) were pumped in equal amounts to a vessel, where a residence time for AEX 
adsorption of 15 min was applied, with the aim of allowing contaminants to adsorb to the resin. The resulting 
supernatant/AEX resin suspension was pumped out of the vessel into a 0.22-µm hollow fiber system (GE, USA). 
The mAb was recovered in the permeate, whereas the AEX resin remained in the retentate and could undergo 
elution, regeneration and sanitization for reusing. Two process variations were evaluated (Table 1), which were 
combined resulted in 6 different process strategies: (i) the ratio of clarified supernatant to AEX resin; (ii) the use 
of a device for cell/flocs retention named inclined lamella settler (Biotechnology Solutions, USA) and depth filter 
Clarisolve (Merck, USA), both were placed after the flocculation step to ensure a cleaner supernatant and to 
allow reducing the cell settling time. The integrated clarification-capture process showed to be simple and fast. 
Steady-state conditions were obtained during adsorption and filtration for all conditions studied. The average 
recovery of mAb during the steady-state was 48.5% ± 2%, which means a loss of approximately 3% of mAb 
product, since it was 2-fold diluted by the 1:1 mix with the resin suspension. However, considering the overall 
process, from start to final permeate recovery, global yields between 61% and 90% were obtained. These 
results are mainly related to the void volume of inclined lamella settler. The best global recovery (90.4%) was 
obtained when the depth filter was included in the process. Regarding impurities removal, in all 6 process 
strategies evaluated more than 85% of DNA was removed, and approximately 70% of HCP removal could be 
achieved when depth filter was used. Taking into account that two different supernatant/AEX resin ratios tested, 
a lower supernatant/resin ratio (41) provided a higher DNA clearance (86 fold), compared to less than one third 
of this clearance when sample/resin ratio was doubled to 82. 
 
Table 1: Straight-through process variations studied. 
 
 
 
 
 
 
 
 
